Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Balancing risk and reward: the question of natalizumab.

× No keyword cloud information.

5 in total

1. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.

Authors: Marta Melis; Eleonora Cocco; Jessica Frau; Lorena Lorefice; Giuseppe Fenu; Giancarlo Coghe; Marco Mura; Maria Giovanna Marrosu
Journal: Neurol Sci Date: 2013-08-30 Impact factor: 3.307

2. Medical decisions are not just about the facts: What a life-threatening virus can teach us about empathy, psychology, and the practice of neurology.

Authors: Norman J Kachuck
Journal: Neurol Clin Pract Date: 2012-06

3. Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors: Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal: J Neurol Date: 2016-05-18 Impact factor: 4.849

4. When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis.

Authors: Norman J Kachuck
Journal: Neuropsychiatr Dis Treat Date: 2011-04-19 Impact factor: 2.570

5. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.

Authors: Georgios Tsivgoulis; Aristeidis H Katsanos; Dimitris Mavridis; Nikolaos Grigoriadis; Efthymios Dardiotis; Ioannis Heliopoulos; Panagiotis Papathanasopoulos; Theodoros Karapanayiotides; Constantinos Kilidireas; Georgios M Hadjigeorgiou; Konstantinos Voumvourakis
Journal: PLoS One Date: 2016-09-29 Impact factor: 3.240

5 in total